Introduction
Hypoglycemia in neonates has been recognized as a cause of serious long-term morbidity for over 50 years. However, because low blood glucose is a surrogate marker for central nervous system energy deficiency, the correlation between level of glycemia, central nervous system damage, and long-term outcome remains unclear. With the development of newer imaging modalities for the central nervous system, a better picture of the effect of low central nervous system glucose on neural development has emerged and has been supplemented by experimental studies examining the mechanism of hypoglycemic damage. In addition, new information has developed about various causes of hypoglycemia, treatment, and prevention. These topics are the focus of this review.
Glucose measurement and diagnosis of hypoglycemia
Measurement of blood glucose and the relationship of serum glucose levels to central nervous system energy balance still remain controversial. In 2000, a consensus conference suggested operational thresholds for treatment of neonatal hypoglycemia [1] . For the term healthy infant with normal pregnancy and delivery, no glucose monitoring was indicated. Glucose measurement was recommended for symptomatic neonates. Those with known risk factors were to be screened within 2-3 h of birth. A symptomatic neonate with a glucose concentration lower than 45 mg/dl should be treated and if symptoms do not resolve, other causes should be considered. Breast-fed infants were noted to have lower concentrations of blood glucose, but higher serum ketone levels as an alternative central nervous system fuel. A recent consensus workshop on the same topic noted that there is still 'neither a rational basis nor sufficient evidence to identify a specific value or range of plasma glucose concentrations that would define hypoglycemia. . .. ' [2 ] .
Plasma glucose values as low as 40-45 mg/dl may be identified in 5-15% of normal newborns [2 ] . However, method of measurement and site of measurement may influence these results. Plasma glucose is 10% or more higher than whole blood glucose. One commonly used point of care device overestimated blood glucose, particularly in the low ranges, in immature infants, compared with traditional laboratory methods, but it is unclear whether the effect of storage and transport was taken into account. Glycolysis is greater in neonatal blood samples [3, 4] . In addition, central venous blood glucose measurements may be higher than arterial blood glucose levels in very ill children [5] .
A recent case-control study of the incidence of hypoglycemia in neonates from term, singleton nondiabetic pregnancies in a single hospital in the USA used a glucose of less than 50 mg/dl to diagnose hypoglycemia. In infants weighing more than 2500 g, hypoglycemia prevalence was 2.4% and was more common in infants whose mothers were febrile during labor, had public rather than private insurance, and were somewhat earlier in gestational age. However, because these neonates did not have serial glucose measures performed, the true prevalence of glucose less than 50 mg/dl was not determined [6] . Data extracted from the Swedish Perinatal Quality Register were used to evaluate hospitalization length in 2388 infants. Hypoglycemia (level of blood glucose not defined) was one of many risk factors that increased the initial hospitalization length of stay for moderately preterm neonates. Exclusively or partially breast-fed infants had a decreased risk of hypoglycemia and were younger at discharge [7] .
Diagnosis and management of hypoglycemia was shown to be enhanced by the refinement of a protocol for the collection and analysis of samples ('Hypopack'). Twentyfive percent of 100 audited collections of 'Hypopacks' were in children less than 1 month of age and in those newborns, half were determined to have 'true hypoglycemia' (glucose less than 2.6 mmol/l or 47 mg/dl). The Hypopack permitted the identification of hyperinsulinism, adrenocorticotropic hormone (ACTH) deficiency, and medium chain acyl-CoA dehydrogenase deficiency. Hypopacks included a preprinted laboratory form with a fluoride oxalate tube for the collection of blood for glucose, b-hydroxybutyrate and lactate, a plain clotted tube for insulin, cortisol, growth hormone and amino acids, a heel-stick blood collection card for acyl-carnitine profile, and a urine collecting bottle for organic acids [8] .
Cause of neonatal hypoglycemia
Recent studies have examined aspects of hypoglycemia associated with hyperinsulinism.
Infants of diabetic mothers
Maternal diabetes with poor glycemic control leads to chronic hyperglycemia in utero and is a common cause of transient neonatal hyperinsulinemia and hypoglycemia. The HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes) proved that maternal hyperglycemia less severe than diabetes is associated with adverse pregnancy outcomes, including neonatal hypoglycemia. This large prospective multicenter study found an association between maternal glucose levels, increased birth weight, and increased cord-blood serum C-peptide levels. Clinical hypoglycemia defined as evidence of symptomatic hypoglycemia requiring glucose infusion, or a blood glucose of 30.6 mg/dl or less in the first 24 h, or 45 mg/dl or less after this was identified in 2.1% of the newborns. Prevalence doubled in those whose mothers had the highest fasting blood glucoses [9] . However, a recent study found a lower birth weight, but no reduction in neonatal hypoglycemia in the infants of women with mild gestational diabetes mellitus who were treated during pregnancy with dietary intervention and insulin as necessary. Approximately, 15% of infants born to treated and untreated women had blood glucose levels of less than 35 mg/dl within 2 h of birth and before feeding [10] .
Large for gestational age neonates
Large for gestational age (LGA) babies have an increased risk of hypoglycemia even when they are not the products of diabetic pregnancies. In a retrospective review of the outcomes of infants whose mothers had gestational diabetes mellitus, the risk of hypoglycemia (glucose less than 40 mg/dl, timing of sample not stated) was 5.3% in infants weighing 4000 g or greater, compared with 2.6% in infants whose birth weight was less than 4000 g. However,
LGA infants who were not the products of pregnancies complicated by diabetes also had an increased risk of hypoglycemia (2.4 vs. 1.2%) [11] . Confirmatory animal studies have demonstrated increased fetal pancreatic b-cell development and obesity in fetuses of obese pregnant sheep [12] .
Iatrogenic hypoglycemia
Treatment of neonatal hyperglycemia using insulin infusion has been associated with an increased risk of hypoglycemia [13] . Administration of fresh frozen plasma in extremely preterm infants leads to elevated levels of insulin-like growth factor-1 (IGF1), a potential risk factor for hypoglycemia, because it can bind to the insulin receptor. However, in this study, all infants were also receiving glucose infusion and there was no evidence of hypoglycemia [14] .
Genetic hyperinsulinemic hypoglycemia
A number of gene disorders have been shown to lead to hyperinsulinism and hypoglycemia [15] . Congenital hyperinsulinism or persistent hyperinsulinemic hypoglycemia of infancy commonly results from mutations in the genes encoding the pancreatic b-cell ATP-sensitive potassium channel, ABCC8 and KCNJ22, which encode for SUR1 and Kir6.2. Most of these mutations are recessive and lead to diffuse hyperinsulinism, but dominant mutations exist. Focal hyperinsulinism as a result of paternal uniparental isodisomy, which unmasks a paternally inherited KATP channel mutation on chromosome 11, has a similar clinical presentation, but is amenable to local surgical excision. The molecular genetics of ABCC8 mutations in Norway was reviewed recently. Most probands were of Norwegian ethnicity. Minimum birth prevalence was estimated to be 1 : 70 000, similar to other reports, and 60% were homozygotes or compound heterozygotes with diffuse hyperinsulinism. One had a dominant form of the disease and 30% likely had focal disease. Sixteen potentially pathogenic mutations were identified, some not previously reported. Therefore, this is a diverse disorder without a 'founder effect' in the Norwegian population [16] . A recent case report from the USA additionally suggested that some individuals with this disorder could have developmental abnormalities of the pancreas with localized adenomatous hyperplasia despite the presence of compound heterozygosity [17] .
The association of hyperinsulinism and hyperammonemia (HI/HA) related to activating mutations in glutamate dehydrogenase (GDH) encoded by GLUD1 was initially reported in 1998 [18] . The phenotype of the disorder has expanded. A recent review of 20 patients revealed one hyperinsulinemic individual with a confirmed mutation who did not have hyperammonemia. In addition, almost half had a seizure disorder, perhaps related to the high expression of the gene in the brain. Increased birth weight was not a constant finding and only a few presented with hypoglycemia in the first week of life [19 ] .
Hyperinsulinism and hypoglycemia have also been associated with loss of function mutations in the hepatocyte nuclear factor 4-a (HNF4A) gene. This is of interest because mutations in this gene are associated with MODY 1, one form of autosomal dominant diabetes mellitus (Maturity Onset Diabetes of the Young) responsive to sulfonylureas. A number of reports have now described macrosomia and persistent hypoglycemia in affected infants with a MODY 1 mutation. The cause of the hypoglycemia is uncertain. Many of these babies develop MODY 1 with age [20] .
Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, (HADH; previously known as short-chain L-3-hydroxyacyl-CoA dehydrogenase or SCHAD), is also associated with hyperinsulinism. HADH is required for the regulation of basal insulin release by the b-cell, but the exact mechanism is unclear [21] . Not all children with this molecular disorder will have diagnostic abnormalities in plasma organic acids, but they may be exquisitely sensitive to dietary protein-induced hypoglycemia [22] . One child was imaged with 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/computed tomography (CT), an imaging modality previously used to separate out diffuse and focal forms of hyperinsulinism secondary to mutations in the b-cell ATP-sensitive potassium channel and had diffuse b-cell hyperactivity [23] . These children may require treatment with diazoxide as neonates.
Prevention and treatment of neonatal hypoglycemia
A prospective controlled trial of administration of 30 mg of epinephrine immediately after elective term cesarean section birth did not decrease the risk of asymptomatic hypoglycemia (blood glucose less than 1.8 mmol/l or 32.4 mg/dl) 2 h after birth (5.9%) [24] . Treatment of neonatal hypoglycemia initially requires provision of exogenous glucose often in high concentration. In general, recommended infusions into peripheral veins are no more than 15% glucose. However, a study of 121 Finnish newborns with hypoglycemia randomly assigned to receive 20 or 15% glucose infusion because of hypoglycemia did not demonstrate that there were more complications with the higher concentration of glucose [25] .
Two recent approaches to the prevention of neonatal hypoglycemia in infants of diabetic women might be promising. In one small retrospective study, early breastfeeding substantially decreased the risk of neonatal hypoglycemia in infants of women with gestational diabetes. Neonates who were breast-fed within 30 min of birth in the delivery room had significantly lower rates of 'borderline hypoglycemia' (2.48 mmol/l or 44.6 mg/dl) compared with infants who received an early formula feed (9 vs. 46%) and those who received later breast-feeding [26] . If these findings were to be replicated prospectively, early breast-feeding would be a simple and noninvasive method to decrease the risk of hypoglycemia in infants of diabetic women. A more invasive approach also seemed to reduce the risk. Eighteen pregnant women with type 1 diabetes were given insulin using guidance from real time continuous glucose monitoring, during treatment with betamethasone to prevent respiratory distress in their infants, and during delivery. Newborns did not develop hypoglycemia in the first 72 h after birth [27] .
A few recent reports suggested alternative means of therapy for children with hyperinsulinemic hypoglycemia. Subcutaneous glucagon has been given for weeks to months in order to avoid surgery. In several patients, glucagon infusion was added to reduce the dose of octreotide. A new, more stable preparation of glucagon permitted such long-term therapy in diazoxide insensitive children who had generalized disease [28] . A laparoscopic approach to pancreatectomy was proved feasible in 10 older infants and children with persistent hyperinsulinism [29] .
Mechanism of hypoglycemic brain damage
Loss of cerebral energy substrate enhances the encephalopathy and ischemic brain damage of perinatal asphyxia in neonates. Hypoglycemia associated with asphyxia leads to more severe encephalopathy and central nervous system damage [30 ] .
The mechanism of the permanent neuronal damage following hypoglycemia is not fully understood. In a rat model of hypoglycemic neuronal injury, activation of neuronal NADPH oxidase during glucose reperfusion led to superoxide production and neuronal cell death. This could be inhibited by blockade of NADPH production [31] . In another study using an adult rat model, neuroprotection following traumatic brain injury was enhanced by fasting because of induction of ketosis, rather than hypoglycemia. This effect could be mimicked by administration of ketones, but not by induction of hypoglycemia with insulin. Preservation of normal mitochondrial function by ketones seems to be mechanistic. This offers an explanation for the severity of hypoglycemic brain damage in individuals with hyperinsulinism and low levels of ketogenesis [32] .
Magnetic resonance imaging (MRI) evaluation of 60 children who had been diagnosed with neonatal hypoglycemia and had neurologic sequelae, including mental retardation, seizure disorder, microcephaly, and attention deficit disorder revealed characteristic abnormal high intensity imaging in T2-weighted images in the periventricular deep white matter and/or adjacent atrophy in the cerebral cortex with loss of gray-white matter differentiation in the parietooccipital lobes and in the occipital region. A few patients had multicystic encephalomalacia. Blood glucose levels less than 30 mg/dl were more likely to be associated with severe MRI findings. The pattern of occipital injury has been previously reported and separates out the MRI findings of hypoglycemia from those of hypoxic ischemic encephalopathy [33] . It is associated with cortical visual defects. In a cohort of 45 neonates, diffusion-weighted imaging studies performed within 6 days after initial hypoglycemia correlated with defects in term but not preterm neonates. All infants had good glucose control by 8 days of age, and the diagnoses were varied. Occipital diffusion restriction was seen in eight of 16 term neonates and none of nine premature infants. More than half the neonates had a poor cortical visual-evoked potential response and there was a significant association with the restricted occipital diffusion pattern. All neonates had blood glucose less than 2.1 mmol/l (38 mg/dl). Only infants who had documented hypoglycemia on more than 1 day had cortical visual defects later. In a followup of some of these infants, microcephaly, seizure disorder, and cortical blindness were common sequelae and MRI findings were occasionally not localized only to the occipital-parietal region [34] . In another recent study, MRIs performed between 1 and 42 days in infants with varying severity of hypoglycemic events revealed a wide range of abnormalities, not in general limited to the occipital and parietal cortex. However, the initial white matter damage identified on MRI correlated better with neurologic outcome at 18 months than did the pattern of blood glucose [35 ] . Proton magnetic resonance spectroscopy (H-MRS) has been used to define the nature of the central nervous system insult in a few patients. Abnormal H-MRS may be a more useful predictor of outcome in hypoglycemic-ischemic encephalopathy than diffusion-weighted imaging alone. Cytotoxic edema, reduced N-acetylaspartate, and increased lactate have been associated with poor neurologic outcome, whereas a normal H-MRS has been anecdotally associated with good outcome [36] .
One study on rats suggests that postnatal age influences hypoglycemia-induced neuronal injury, with younger rats more able to withstand such injury. In addition, repetitive hypoglycemia in a neonatal animal model leads to more severe hypoglycemic central nervous system damage than shorter exposure to hypoglycemia [37] . Elevated levels of ketone bodies and greater central nervous system glycogen stores might provide alternative energy sources for the cerebral cortex in these younger animals. Use of alternative energy substrates has long been postulated as a protective mechanism in human infants with hypoglycemia associated with high levels of alternative neural substrates [38] .
Conclusion
The definition of neonatal hypoglycemia remains unclear because peripheral blood glucose remains a surrogate marker for neuronal energy supply. Hypoglycemia associated with elevated levels of alternative energy substrates such as ketones and lactate may be far less damaging to the central nervous system than hypoglycemia associated with hyperinsulinism. Nonetheless, in the past several years, new information has accrued as to the diagnosis, cause, and management of hyperinsulinemic hypoglycemia secondary to maternal and genetic causes. In addition, newer imaging techniques such as diffusionweighted MRI and MRS are offering increased information about the effect of energy substrate deficiency on the brain and the relationship of acute deficiencies to long-term neurologic deficit. More prospective studies using imaging modalities to examine central nervous system energy supply may finally permit the development of direct means of assessing neuronal energy needs in vivo.
